Research and Markets: In Saudi Arabia, the Prevalence of Type 2 Diabetes Is Expected To Rise To Between 40-50% By 2020 Says Latest Research Report

(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:11022009

Dublin - Research and
Markets(http://www.researchandmarkets.com/research/7702ac/stakeholder_op
inio) has announced the addition of the "Stakeholder Opinions: Type 2
Diabetes in the UAE & Saudi Arabia - Growth Opportunities in Fragmented
Markets" report to their offering.

Introduction

This report focuses on the challenges of diverse and uncoordinated
treatment paradigms for diabetes and the movement to rationalize
efforts and establish best practice. Datamonitor uncovers the unique
dynamics of the two largest diabetes markets in the GCC; including the
impact of regulatory processes such as the healthcare reforms currently
being undertaken.

Scope

- Description and analysis of the uniqueness of the antidiabetic
markets in the UAE and Saudi Arabia

- Fragmented healthcare delivery in the UAE and Saudi Arabia presents
opportunity for ramping up sales of generics and novel antidiabetic
therapeutics.

- Commercial implications of the extensive findings and our
recommendations to maximize sales in these two markets.

Highlights

Diabetes has reached near-epidemic proportions in the UAE and Saudi
Arabia, with nearly one out of every five individuals suffering from
diabetes in the UAE. In Saudi Arabia, the prevalence is expected to
rise to between 40-50% by 2020.

The delivery of treatment for diabetes is highly fragmented, and leads
to sub-optimal treatment for patients in the two countries. The
fragmentation is caused by a wide variety of issues due to systemic
deficiencies, regulatory changes and socio-economic factors.

Datamonitor has explained the commercial implications of its findings
and developed recommendations for healthcare firms and regulators to
address the many unmet needs in the treatment of diabetes and to ramp
up sales and share of market in both UAE and Saudi Arabia.

Reasons to Purchase

- Gain an in-depth understanding of the two largest diabetes markets in
the GCC; a strategic growth area for healthcare firms.

- Increase share of the market by effectively targeting the different
segments of the population and demands; branded or generic antidiabetic
agents.

[ Back To Transforming Network Infrastructure's Homepage ]